[1] Gusarova V, Alexa CA, Na E, et al. ANGPTL8/betatrophin does not control pancreatic beta cell expansion[J]. Cell, 2014, 159(3):691-696. [2] Yi P, Park JS, Melton DA. Betatrophin:A hormone that controls pancreatic beta cell proliferation[J]. Cell, 2013, 153(4):747-758. [3] Jiao Y, Le L, Yu M, et al. Elevated mouse hepatic ANGPTL8 expression does not increase human beta-cell replication in the transplant setting[J]. Diabetes, 2014, 63(4):1283-1288. [4] Fu Z, Berhane F, Fite A, et al. Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity[J]. Scientific Reports, 2014, 4(11):5013. [5] Daniel MM, Per OC. Increased circulating betatrophin concentrations in patients with type 2 diabetes[J]. Int J Endocrinol, 2014, 10(5):323407-323413. [6] Tokumoto HY, Fujimoto K, Yamaguchi E, et al. Correlation of circulating betatrophin concentrations with insulin secretion capacity, evaluated by glucagon stimulation tests[J]. J Clin Endocr Metab, 2015, 19(1):111-119. [7] Chen X, Lu P, He W, et al. Circulating betatrophin levels are increased in patients with type 2 diabetes and associated with insulin resistance[J]. J Clin Endocrinol Metab, 2015, 100(1):E96-E100. [8] Hu H, Sun W, et al. Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients[J]. Diabetes Care, 2014, 37(10):2718-2722. [9] Viktoria G, Erqian Na, Panayiotis E, et al. ANGPTL8/betatrophin does not control pancreatic beta cell expansion[J]. Cell, 2014, 159:691-696. [10] Yi P, Park JS, Melton DA. Perspectives on the activities of ANGPTL8/betatrophin[J]. Cell, 2014, 159(3):467-468. [11] Zhou L, Sell H, Eckardt K, et al. Conditioned medium obtained from in vitro differentiated adipocytes and resistin induce insulin resista-nce in human hepatocytes[J]. Febs Letters, 2007, 581(22):4303-4308. [12] Neri LM, Borgatti P, Capitani S, et al. The nuclear phosphoinositide 3-kinase/AKT pathway:a new second messenger system[J]. Biochimica et Biophysica Acta, 2002, 1584(23):73-80. [13] Cantley LC. The phosphoinositide 3-kinase pathway[J]. Science, 2002, 296(5573):1655-1657. [14] Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide 3-kinase pathway in cancer[J]. Nat Rev Drug Discov, 2009, 8(8):627-644. [15] Lochhead PA, Coghlan M, Rice SQ, et al. Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression[J]. Diabetes, 2001, 50(5):937-946. [16] Ishikawa M, Yoshida K, Okamura H, et al. Oral porphyromonas gingivalis translocates to the liver and regulates hepatic glycogen synthesis through the AKT/GSK-3beta signaling pathway[J]. Biochimica et Biophysica Acta, 2013, 1832(12):2035-2043. [17] Banks MJ, Mastracci TL, Kofler NM, et al. Dissociation of the glucose and lipid regulatory functions of FoxO1 by targeted knock in of acetylation-defective alleles in mice[J]. Cell Metab, 2011, 14(5):587-597. [18] Zhang R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels[J]. Biochem Bioph Res Co, 2012, 424(4):786-792. [19] Fu ZY, Yao FY, Abou-Samra AB, et al. Lipasin, thermoregulated in brown fat, is a novel but atypical member of the angiopoietin-like protein family[J]. Biochem Bioph Res Co, 2013, 430(3):1126-1131. [20] Ren G, Kim JY, Smas CM. Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism[J]. Am J Physiol Endocrinol Metab, 2012, 303(3):E334-351. [21] 郭兴荣, 陈云, 李东升. TALEN介导的Betatrophin敲除HepG2细胞株的建立[J]. 湖北医药学院学报, 2015, 10(5):427-431. |